Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism
- PMID: 2271373
- PMCID: PMC1368175
- DOI: 10.1111/j.1365-2125.1990.tb03844.x
Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism
Abstract
1. The effect of severe hypothyroidism on the pharmacokinetics and pharmacodynamics of oxazepam 15 mg given orally (n = 10) and the metabolism of paracetamol 750 mg given intravenously (n = 8) was investigated before and after treatment with levothyroxine. 2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01). 3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05). 4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid. 5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01). This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1. 6. Hypothyroidism was associated with decreased performance in a finger tapping test that was exacerbated by oxazepam. When the patients were euthyroid oxazepam did not produce any effect.
Similar articles
-
Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects.Br J Clin Pharmacol. 1991 Jun;31(6):719-22. doi: 10.1111/j.1365-2125.1991.tb05602.x. Br J Clin Pharmacol. 1991. PMID: 1867967 Free PMC article. Clinical Trial.
-
Bioavailability and pharmacokinetics of oxazepam.Eur J Clin Pharmacol. 1988;35(4):385-9. doi: 10.1007/BF00561369. Eur J Clin Pharmacol. 1988. PMID: 3197746
-
Factors and conditions affecting the glucuronidation of oxazepam.Pharmacol Toxicol. 1993;73 Suppl 1:1-23. doi: 10.1111/j.1600-0773.1993.tb01924.x. Pharmacol Toxicol. 1993. PMID: 8415417 Review.
-
Oxazepam pharmacokinetics in thyroid disease.Br J Clin Pharmacol. 1984 Jan;17(1):49-53. doi: 10.1111/j.1365-2125.1984.tb04998.x. Br J Clin Pharmacol. 1984. PMID: 6419761 Free PMC article.
-
Clinical pharmacokinetics of oxazepam and lorazepam.Clin Pharmacokinet. 1981 Mar-Apr;6(2):89-105. doi: 10.2165/00003088-198106020-00001. Clin Pharmacokinet. 1981. PMID: 6111408 Review.
Cited by
-
Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers.Int J Mol Sci. 2023 Feb 25;24(5):4543. doi: 10.3390/ijms24054543. Int J Mol Sci. 2023. PMID: 36901973 Free PMC article.
-
Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.Clin Pharmacokinet. 1992 Oct;23(4):292-310. doi: 10.2165/00003088-199223040-00005. Clin Pharmacokinet. 1992. PMID: 1395362 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous